View ValuationProtagenic Therapeutics 将来の成長Future 基準チェック /06現在、 Protagenic Therapeuticsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長25.3%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Feb 19Protagenic Therapeutics, Inc. announced delayed 10-Q filingOn 02/18/2026, Protagenic Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jan 16Nasdaq Stock Market to Delist Common Stock of Protagenic Therapeutics, IncThe Nasdaq Stock Market announced that it will delist the common stock, and warrants of Protagenic Therapeutics, Inc. Protagenic Therapeutics, Inc.’s securities were suspended on January 5, 2026 and have not traded on Nasdaq since that time.お知らせ • Jan 05Protagenic Therapeutics Receives Delisting Notice from NasdaqBeginning January 5, 2026, Protagenic Therapeutics, Inc. (the Company") expects its common stock (PTIX") and warrants (PTIXW") to be quoted for trading on the over-the-counter market. On December 31, 2025, the Company received a letter from The Nasdaq Stock Market LLC (Nasdaq") stating that trading of the Company's securities on Nasdaq would cease at the close of trading on January 2, 2026, and that Nasdaq determined to delist the Company's securities based on the Company's failure to satisfy Nasdaq continued listing requirements, including Nasdaq Listing Rule 5550(b)(1) (minimum stockholders' equity) and Nasdaq Listing Rule 5250(c)(1) (timely filing of periodic reports). OTC trading is effected through registered broker-dealers, and quotation and trading information is generally available through brokerage platforms and publicly available quotation services. The Company intends to continue to file periodic and current reports with the SEC, which will be available on the SEC's EDGAR system. The OTC market may have different liquidity and trading characteristics than a national securities exchange. The Company is evaluating steps to regain compliance with Nasdaq listing requirements and to seek relisting on Nasdaq. The Company also intends to engage with market participants to facilitate the OTC transition and support liquidity in its securities. The Company has withdrawn its request for a hearing before a Nasdaq Hearings Panel and, accordingly, Nasdaq's determination is final.お知らせ • Dec 08Protagenic Therapeutics, Inc., Annual General Meeting, Dec 31, 2025Protagenic Therapeutics, Inc., Annual General Meeting, Dec 31, 2025.お知らせ • Nov 27Protagenic Therapeutics, Inc. Receives Notification Letter from Nasdaq Delisting Due to Non-Compliance with Listing RulesOn November 20, 2025, Protagenic Therapeutics, Inc. received a notification letter (the “Notice”) from the Nasdaq Listing Qualifications Staff (the “Staff”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(1) (minimum stockholders’ equity of $2,500,000) and Nasdaq Listing Rule 5250(c)(1) (timely filing of periodic reports). As reported in the Company’s Transition Report on Form 10-QT for the period ended June 30, 2025, the Company’s stockholders’ equity no longer satisfies the minimum requirement of Rule 5550(b)(1). The Staff also cited the Company’s delated filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 as a separate basis for non-compliance under Rule 5250(c)(1). The Company is completing final steps for the Form 10-Q and expects to file it imminently. Because the Company had only recently regained compliance and remains subject to a mandatory one-year panel monitoring period under Nasdaq Listing Rule 5815(d)(4)(B), the Staff issued a determination to delist the Company’s securities from The Nasdaq Capital Market. The Company intends to timely request a hearing before a Nasdaq Hearings Panel (the “Panel”) to appeal the Staff’s determination. A timely hearing request will automatically stay any suspension of the Company’s securities for 15 calendar days. The Company will also request that the Panel a stay any suspension, pending the outcome of the hearing. During the automatic stay—and, if granted, during any extended stay—the Company’s common stock will continue to trade on The Nasdaq Capital Market. There can be no assurance that the Panel will grant the Company’s request for an extended stay or that the Company will regain compliance with Nasdaq’s continued listing standards.お知らせ • Nov 15Protagenic Therapeutics, Inc. announced delayed 10-Q filingOn 11/14/2025, Protagenic Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 23Protagenic Therapeutics Receives Notice of Non-Compliance from Nasdaq Due to Delayed Filing of Form 10-QAs disclosed in the Company’s Form 12b-25 filed on August 14, 2025, Protagenic Therapeutics, Inc. is finalizing merger-related consolidation of financial statements for the quarter ended June 30, 2025, including purchase accounting adjustments, pro forma financial information, and related disclosures. These procedures are being completed under Audit Committee oversight with the Company’s independent auditors and external advisors. The Company expects to file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 (the ‘Form 10-Q’) in the near future. On August 20, 2025, the Company received a notice (the ‘Notification Letter’) from the Nasdaq Listing Qualifications department (‘Nasdaq’) stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of the Form 10-Q. The notice does not immediately effect the listing or trading of the Company’s securities, which continue to trade on the Nasdaq Capital Market under the symbol ‘PTIX.’ The Company intends to submit a plan to regain compliance within 60 calendar days of the Notification Letter, and Nasdaq may grant an exception of up to 180 calendar days from the Form 10-Q’s due date.お知らせ • Aug 15Protagenic Therapeutics, Inc. announced delayed 10-Q filingOn 08/14/2025, Protagenic Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.New Risk • Aug 11New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$2.46m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (US$2.46m market cap). Minor Risk Share price has been volatile over the past 3 months (16% average weekly change). このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Protagenic Therapeutics は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:PTIX - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数アナリストによる今後の成長予測収入対貯蓄率: PTIXの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: PTIXの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: PTIXの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: PTIXの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: PTIXの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: PTIXの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/27 12:28終値2026/05/27 00:00収益N/A年間収益N/Aデータソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Protagenic Therapeutics, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Feb 19Protagenic Therapeutics, Inc. announced delayed 10-Q filingOn 02/18/2026, Protagenic Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jan 16Nasdaq Stock Market to Delist Common Stock of Protagenic Therapeutics, IncThe Nasdaq Stock Market announced that it will delist the common stock, and warrants of Protagenic Therapeutics, Inc. Protagenic Therapeutics, Inc.’s securities were suspended on January 5, 2026 and have not traded on Nasdaq since that time.
お知らせ • Jan 05Protagenic Therapeutics Receives Delisting Notice from NasdaqBeginning January 5, 2026, Protagenic Therapeutics, Inc. (the Company") expects its common stock (PTIX") and warrants (PTIXW") to be quoted for trading on the over-the-counter market. On December 31, 2025, the Company received a letter from The Nasdaq Stock Market LLC (Nasdaq") stating that trading of the Company's securities on Nasdaq would cease at the close of trading on January 2, 2026, and that Nasdaq determined to delist the Company's securities based on the Company's failure to satisfy Nasdaq continued listing requirements, including Nasdaq Listing Rule 5550(b)(1) (minimum stockholders' equity) and Nasdaq Listing Rule 5250(c)(1) (timely filing of periodic reports). OTC trading is effected through registered broker-dealers, and quotation and trading information is generally available through brokerage platforms and publicly available quotation services. The Company intends to continue to file periodic and current reports with the SEC, which will be available on the SEC's EDGAR system. The OTC market may have different liquidity and trading characteristics than a national securities exchange. The Company is evaluating steps to regain compliance with Nasdaq listing requirements and to seek relisting on Nasdaq. The Company also intends to engage with market participants to facilitate the OTC transition and support liquidity in its securities. The Company has withdrawn its request for a hearing before a Nasdaq Hearings Panel and, accordingly, Nasdaq's determination is final.
お知らせ • Dec 08Protagenic Therapeutics, Inc., Annual General Meeting, Dec 31, 2025Protagenic Therapeutics, Inc., Annual General Meeting, Dec 31, 2025.
お知らせ • Nov 27Protagenic Therapeutics, Inc. Receives Notification Letter from Nasdaq Delisting Due to Non-Compliance with Listing RulesOn November 20, 2025, Protagenic Therapeutics, Inc. received a notification letter (the “Notice”) from the Nasdaq Listing Qualifications Staff (the “Staff”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(1) (minimum stockholders’ equity of $2,500,000) and Nasdaq Listing Rule 5250(c)(1) (timely filing of periodic reports). As reported in the Company’s Transition Report on Form 10-QT for the period ended June 30, 2025, the Company’s stockholders’ equity no longer satisfies the minimum requirement of Rule 5550(b)(1). The Staff also cited the Company’s delated filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 as a separate basis for non-compliance under Rule 5250(c)(1). The Company is completing final steps for the Form 10-Q and expects to file it imminently. Because the Company had only recently regained compliance and remains subject to a mandatory one-year panel monitoring period under Nasdaq Listing Rule 5815(d)(4)(B), the Staff issued a determination to delist the Company’s securities from The Nasdaq Capital Market. The Company intends to timely request a hearing before a Nasdaq Hearings Panel (the “Panel”) to appeal the Staff’s determination. A timely hearing request will automatically stay any suspension of the Company’s securities for 15 calendar days. The Company will also request that the Panel a stay any suspension, pending the outcome of the hearing. During the automatic stay—and, if granted, during any extended stay—the Company’s common stock will continue to trade on The Nasdaq Capital Market. There can be no assurance that the Panel will grant the Company’s request for an extended stay or that the Company will regain compliance with Nasdaq’s continued listing standards.
お知らせ • Nov 15Protagenic Therapeutics, Inc. announced delayed 10-Q filingOn 11/14/2025, Protagenic Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 23Protagenic Therapeutics Receives Notice of Non-Compliance from Nasdaq Due to Delayed Filing of Form 10-QAs disclosed in the Company’s Form 12b-25 filed on August 14, 2025, Protagenic Therapeutics, Inc. is finalizing merger-related consolidation of financial statements for the quarter ended June 30, 2025, including purchase accounting adjustments, pro forma financial information, and related disclosures. These procedures are being completed under Audit Committee oversight with the Company’s independent auditors and external advisors. The Company expects to file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 (the ‘Form 10-Q’) in the near future. On August 20, 2025, the Company received a notice (the ‘Notification Letter’) from the Nasdaq Listing Qualifications department (‘Nasdaq’) stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of the Form 10-Q. The notice does not immediately effect the listing or trading of the Company’s securities, which continue to trade on the Nasdaq Capital Market under the symbol ‘PTIX.’ The Company intends to submit a plan to regain compliance within 60 calendar days of the Notification Letter, and Nasdaq may grant an exception of up to 180 calendar days from the Form 10-Q’s due date.
お知らせ • Aug 15Protagenic Therapeutics, Inc. announced delayed 10-Q filingOn 08/14/2025, Protagenic Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
New Risk • Aug 11New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$2.46m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (US$2.46m market cap). Minor Risk Share price has been volatile over the past 3 months (16% average weekly change).